PRKN and Parkinson disease: For example, PARK2 knockout human iPSC derived neural cells, a model of Parkinson’s disease, showed that increased Rho signaling was accompanied by decreased levels of phospho-MPRIP, impaired neurite outgrowth and increased cell migration whereas pharmacological inhibition of RhoA signaling in this model resulted in improved neurite outgrowth and decreased cell migration [65].